CX3C Chemokine Receptor 1

Receptor for CHEMOKINE CX3CL1 expressed by lymphocytes, neurons, and GLIAL CELLS. Its interaction with CX3CL1 mediates CELL ADHESION and CELL MIGRATION. It also functions as a co-receptor with the CD4 ANTIGEN for HIV-1 in vitro.

Also Known As:

Networked: 182 relevant articles (2 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ransohoff, Richard M: 7 articles (01/2022 - 06/2010)
2.	Cardona, Astrid E: 5 articles (01/2022 - 08/2013)
3.	Cardona, Sandra M: 3 articles (01/2022 - 08/2013)
4.	Malcangio, Marzia: 3 articles (12/2019 - 08/2010)
5.	Tacke, Frank: 3 articles (01/2019 - 02/2008)
6.	Imai, Toshio: 3 articles (11/2017 - 05/2005)
7.	Bhaskar, Kiran: 3 articles (12/2016 - 01/2015)
8.	Kokiko-Cochran, Olga N: 3 articles (12/2016 - 01/2015)
9.	Lamb, Bruce T: 3 articles (12/2016 - 01/2015)
10.	Maphis, Nicole: 3 articles (12/2016 - 01/2015)

Related Diseases

1.	Acute Kidney Injury (Acute Renal Failure) 01/01/2008 - "Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice."
2.	Anemia 04/27/2023 - "Our findings support the hypothesis that FKN ameliorates the effects of anemia on the receptivity-related genes and proteins in HEC-1A cells by increasing the secretion of the receptivity-related cytokines via the fractalkine receptor (CX3CR1). "
3.	Inflammation (Inflammations) 01/01/2019 - "In this study, we have investigated the role of the fractalkine receptor CX3CR1 in modulating monocyte-derived dendritic cell (moDC) differentiation during liver inflammation. " 01/01/2018 - "Patients with plaque presented higher signs of UT-induced inflammation and arteries from CKD patients presented higher fractalkine receptor (CX3CR1) tissue expression. " 01/01/2018 - "Role of the Fractalkine Receptor in CNS Autoimmune Inflammation: New Approach Utilizing a Mouse Model Expressing the Human CX3CR1I249/M280 Variant." 01/01/2016 - "We investigated the role of fractalkine receptor CX3CR1 in atherosclerotic inflammation in renal impairment. " 08/01/2013 - "Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation."
4.	Neuroinflammatory Diseases 12/18/2013 - "Many progressive neuroinflammatory disorders that are associated with increased microglial activation, such as Alzheimer's disease, show disruption of the FKN/CX(3)CR1 communication system. " 11/01/2011 - "As elevated neuroinflammation is associated with many age-related neurodegenerative diseases, enhancing FKN/CX(3)CR1 interactions could provide an alternative therapeutic approach to slow age-related neurodegeneration." 01/01/2013 - "Although many polymorphism studies have focused on patients with MS, there is no polymorphism study about the fractalkine receptor which is a chemokine and plays an important role in neuroinflammation and neurodegeneration. " 12/01/2016 - "Chemokine fractalkine receptor (CX3CR1) plays a substantial role in microglial activation and neuroinflammation. " 01/01/2015 - "We have previously demonstrated that microglia-mediated neuroinflammation via deficiency of the microglia-specific chemokine (fractalkine) receptor, CX3CR1, promotes tau pathology and neurodegeneration in a mouse model of LPS-induced systemic inflammation. "
5.	Neurodegenerative Diseases (Neurodegenerative Disease) 11/01/2011 - "As elevated neuroinflammation is associated with many age-related neurodegenerative diseases, enhancing FKN/CX(3)CR1 interactions could provide an alternative therapeutic approach to slow age-related neurodegeneration." 11/09/2011 - "The protective/neurotoxic role of fractalkine (CX3CL1) and its receptor CX3C chemokine receptor 1 (CX3CR1) signaling in neurodegenerative disease is an intricate and highly debated research topic and it is becoming even more complicated as new studies reveal discordant results. " 03/22/2021 - "The C-X3-C motif chemokine receptor 1 (CX3CR1, fractalkine receptor) is associated with neoplastic transformation, inflammation, neurodegenerative diseases and aging, and the small molecule inhibitor KAND567 targeting CX3CR1 (CX3CR1i) is evaluated in clinical trials for acute systemic inflammation upon SARS-CoV-2 infections. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Cytokines
3.	Chemokine CX3CL1
4.	Chemokines
5.	Chemokine Receptors
6.	Neutralizing Antibodies
7.	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
8.	Apolipoproteins E (ApoE)
9.	AMP-Activated Protein Kinases
10.	Toll-Like Receptors (Toll-Like Receptor)

Related Therapies and Procedures

1.	Percutaneous Coronary Intervention
2.	Highly Active Antiretroviral Therapy (HAART)
3.	Kidney Transplantation
4.	Spinal Injections
5.	Renal Dialysis (Hemodialysis)